{"gene":"BCAN","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1994,"finding":"BEHAB/brevican was identified as a brain-specific extracellular matrix protein belonging to the proteoglycan tandem repeat (PTR) family of hyaluronan-binding proteins, with CNS-restricted expression and developmental regulation consistent with a role in stabilizing hyaluronan-proteoglycan interactions in the brain ECM.","method":"cDNA cloning, sequence homology analysis, Northern blot/in situ hybridization for expression profiling","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 3 — foundational cloning/characterization paper; single lab with sequence-based functional inference, replicated across species","pmids":["7512973"],"is_preprint":false},{"year":1995,"finding":"BEHAB/brevican expression in ventricular zones is temporally coincident with gliogenesis (not neurogenesis), suggesting a role in glial cell generation or differentiation during CNS development.","method":"In situ hybridization and immunohistochemistry during rat CNS development","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 3 — localization experiment with developmental timing correlation; single lab","pmids":["7869103"],"is_preprint":false},{"year":1999,"finding":"BEHAB/brevican exists as two isoforms: a secreted form and a GPI-anchored cell-surface form; following intracranial stab wound injury, only the secreted isoform is upregulated during reactive gliosis, temporally paralleling the gliotic response.","method":"Immunoblotting, RNase protection assay, GPI-anchor characterization, stab wound model in adult rat brain","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 — direct fractionation and isoform-specific detection with functional context; single lab","pmids":["10364444"],"is_preprint":false},{"year":2000,"finding":"BEHAB/brevican is cleaved at a specific Glu(395)-Ser(396) site by a constitutively secreted ADAMTS family metalloproteinase, specifically identified as ADAMTS4, in invasive glioma cells (CNS-1 line).","method":"Neoepitope antibody against cleavage site, protease inhibitor panel, RT-PCR, immunoblotting of CNS-1 conditioned medium","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (neoepitope antibody, inhibitor profiling, RT-PCR, immunoblot) in single well-cited study; foundational paper","pmids":["10801887"],"is_preprint":false},{"year":2000,"finding":"Human BEHAB/brevican maps to chromosome 1q31 and is expressed as two isoforms (secreted and GPI-anchored); the secreted isoform is developmentally regulated in human cortex and both isoforms are upregulated ~7-fold in glioma.","method":"RNase protection analysis, chromosomal mapping, cDNA cloning","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 3 — direct isoform characterization and quantification; single lab","pmids":["11054543"],"is_preprint":false},{"year":2001,"finding":"Overexpression of full-length BEHAB/brevican, its N-terminal cleavage product, or C-terminal cleavage product in CNS-1 glioma cells significantly increased tumor aggressiveness and shortened survival in intracranial rat grafts, establishing that both upregulation and proteolytic cleavage of BEHAB/brevican drive glioma invasion.","method":"Stable transfection of glioma cell lines with BEHAB/brevican constructs, intracranial rat graft model, survival analysis, histology","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo loss/gain-of-function with defined phenotypic readout; single lab","pmids":["11585735"],"is_preprint":false},{"year":2003,"finding":"A novel underglycosylated BEHAB/brevican isoform (B/b130), lacking glycosaminoglycan chains and most N-linked sugars, associates with the cell membrane via a calcium-independent mechanism distinct from GPI-anchoring, and is the major isoform upregulated in invasive glioma.","method":"Subcellular fractionation, glycosidase treatment, immunoblotting, rat glioma model","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical fractionation and glycan characterization with functional context; single lab","pmids":["12799382"],"is_preprint":false},{"year":2005,"finding":"Two novel glioma-specific BEHAB/brevican isoforms exist: B/b(sia), an oversialylated form, and B/b(Deltag), which lacks most carbohydrates and associates with the cell surface by a mechanism distinct from GPI-anchoring; B/b(Deltag) is expressed in all high-grade gliomas but absent from indolent oligodendrogliomas.","method":"Biochemical glycan characterization, immunoblotting, surface biotinylation, GPI-anchor disruption assay, analysis of human glioma samples","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods; single lab","pmids":["16061654"],"is_preprint":false},{"year":2008,"finding":"ADAMTS-mediated proteolytic cleavage of BEHAB/brevican at the Glu(395)-Ser(396) site is necessary for its pro-invasive function; a site-specific cleavage-resistant mutant (396SRG→NVY) fails to enhance glioma cell invasion in vitro or tumor progression in vivo, and does not exert dominant-negative effects on endogenous protein.","method":"Site-directed mutagenesis, in vitro invasion assay, intracranial glioma mouse model, immunoblotting","journal":"Journal of neuro-oncology","confidence":"High","confidence_rationale":"Tier 1 — active-site mutagenesis combined with in vitro and in vivo functional assays; mechanistically definitive","pmids":["18398576"],"is_preprint":false},{"year":2011,"finding":"A 15.7 kb deletion spanning three exons of BCAN (encoding brevican) is causally associated with episodic falling syndrome in Cavalier King Charles Spaniels, a paroxysmal hypertonicity disorder, implicating brevican's role in perineuronal net formation, synapse stability, and nerve conduction.","method":"Genome-wide association study, targeted resequencing, deletion breakpoint mapping, MLPA genotyping","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — genetic mapping with deletion identification in canine ortholog model; functional inference from known biology","pmids":["21821125"],"is_preprint":false},{"year":2017,"finding":"A chromosomal microdeletion generating a BCAN-NTRK1 gene fusion acts as a potent oncogenic driver of high-grade gliomas, and tumors harboring this fusion are sensitive to the TRK inhibitor entrectinib.","method":"CRISPR-based somatic chromosomal engineering ex vivo and in vivo, mouse glioma models, pharmacological inhibition","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 — genome editing to generate fusion, multiple mouse models, pharmacological rescue; strong mechanistic demonstration","pmids":["28695888"],"is_preprint":false},{"year":2025,"finding":"Piccolo regulates secretion of brevican (BCAN) and tenascin-R from astrocytes; loss of Piccolo (Pclo gt/gt) causes impaired extracellular brevican levels, fragmented Golgi in astrocytes, reduced synapse density in co-cultured neurons, and altered network activity—rescued by wild-type astrocyte-conditioned media.","method":"Pclo gt/gt rat model, immunohistochemistry, astrocyte-conditioned media rescue, co-culture synapse density assay, mEPSC recording, RNA-seq","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods in a genetic model with functional rescue; preprint, not yet peer-reviewed","pmids":[],"is_preprint":true}],"current_model":"BEHAB/brevican (BCAN) is a brain-specific chondroitin sulfate proteoglycan/hyaluronan-binding protein that exists as secreted and GPI-anchored isoforms and is proteolytically cleaved at Glu395-Ser396 by ADAMTS4; this ADAMTS-mediated cleavage is necessary for BCAN's pro-invasive function in gliomas, while in normal brain BCAN is secreted from astrocytes (regulated by Piccolo at the Golgi) to support perineuronal net formation, synapse stability, and nerve conduction velocity."},"narrative":{"teleology":[{"year":1994,"claim":"Identification of BCAN as a novel brain-restricted hyaluronan-binding proteoglycan established the gene's ECM identity and CNS specificity, opening the question of its functional role in neural tissue.","evidence":"cDNA cloning, sequence homology, and Northern blot/in situ expression profiling in rat brain","pmids":["7512973"],"confidence":"Medium","gaps":["No functional assays performed; role inferred from domain architecture only","Expression profiling limited to rodent"]},{"year":1995,"claim":"Temporal coincidence of BCAN expression with gliogenesis rather than neurogenesis suggested a developmental role in glial lineage specification, raising the question of whether BCAN is functionally required for gliogenesis.","evidence":"In situ hybridization and immunohistochemistry during rat CNS development","pmids":["7869103"],"confidence":"Medium","gaps":["Correlative timing only; no loss-of-function test of gliogenesis requirement","No mechanism linking BCAN to progenitor cell fate"]},{"year":1999,"claim":"Discovery of secreted and GPI-anchored BCAN isoforms, with selective upregulation of the secreted form after brain injury, established isoform-specific regulation and implicated BCAN in the gliotic response.","evidence":"Immunoblotting, RNase protection assay, GPI-anchor characterization, adult rat stab-wound model","pmids":["10364444"],"confidence":"Medium","gaps":["No loss-of-function to test whether secreted isoform upregulation is required for gliosis","Mechanism of isoform-specific transcriptional regulation unknown"]},{"year":2000,"claim":"Identification of ADAMTS4 as the protease cleaving BCAN at Glu395-Ser396 in glioma cells defined the specific proteolytic event central to BCAN processing, setting up the question of whether cleavage is functionally required for invasion.","evidence":"Neoepitope antibody, protease inhibitor profiling, RT-PCR, and immunoblotting of CNS-1 glioma conditioned medium","pmids":["10801887"],"confidence":"High","gaps":["Cleavage shown in one glioma cell line only","Functional consequence of cleavage not yet tested"]},{"year":2001,"claim":"Overexpression of full-length BCAN or either cleavage fragment enhanced glioma aggressiveness in vivo, establishing that both upregulation and proteolytic processing of BCAN promote tumor invasion.","evidence":"Stable transfection of glioma cells, intracranial rat graft model, survival analysis","pmids":["11585735"],"confidence":"Medium","gaps":["Gain-of-function only; no knockdown to test necessity","Mechanism by which cleavage fragments promote invasion unknown"]},{"year":2003,"claim":"Discovery of an underglycosylated, membrane-associated BCAN isoform (B/b130) as the predominant form in glioma revealed that post-translational glycan modification diversifies BCAN cell-surface biology beyond the canonical secreted/GPI dichotomy.","evidence":"Subcellular fractionation, glycosidase treatment, immunoblotting in rat glioma model","pmids":["12799382"],"confidence":"Medium","gaps":["Membrane-association mechanism for the non-GPI form unresolved","Functional contribution of underglycosylated isoform to invasion not directly tested"]},{"year":2005,"claim":"Identification of glioma-specific oversialylated and hypoglycosylated BCAN isoforms that correlate with tumor grade showed that aberrant glycosylation marks aggressive tumors and could serve as biomarkers.","evidence":"Glycan characterization, surface biotinylation, GPI-anchor disruption, human glioma tissue analysis","pmids":["16061654"],"confidence":"Medium","gaps":["Causal role of altered glycosylation in invasion not demonstrated","Mechanism of non-GPI cell-surface retention still unknown"]},{"year":2008,"claim":"A cleavage-resistant BCAN mutant failed to enhance invasion in vitro or tumor progression in vivo, definitively establishing that ADAMTS-mediated cleavage at Glu395-Ser396 is necessary — not merely permissive — for BCAN's pro-invasive activity.","evidence":"Site-directed mutagenesis (396SRG→NVY), in vitro invasion assay, intracranial mouse glioma model","pmids":["18398576"],"confidence":"High","gaps":["Downstream signaling pathways engaged by cleavage fragments remain unidentified","Whether other ADAMTS family members contribute to cleavage in vivo is untested"]},{"year":2011,"claim":"A 15.7 kb BCAN deletion causing episodic falling syndrome in dogs provided the first genetic evidence that BCAN is required for normal neuronal function, linking it to perineuronal net integrity and synaptic/conduction stability.","evidence":"GWAS, targeted resequencing, deletion breakpoint mapping in Cavalier King Charles Spaniels","pmids":["21821125"],"confidence":"Medium","gaps":["Canine model; no human Mendelian disorder confirmed","No rescue experiment to prove causality of the deletion alone","Specific perineuronal net structural defect not visualized"]},{"year":2017,"claim":"CRISPR-engineered BCAN-NTRK1 fusion proved to be an oncogenic driver of high-grade glioma and conferred sensitivity to TRK inhibition, demonstrating that the BCAN locus participates in oncogenic rearrangements beyond its ECM functions.","evidence":"CRISPR somatic engineering of chromosomal deletion in mouse neural progenitors, in vivo tumorigenesis, entrectinib treatment","pmids":["28695888"],"confidence":"High","gaps":["Oncogenic activity driven by NTRK1 kinase domain, not BCAN protein function per se","Frequency and clinical significance of BCAN-NTRK1 fusions in human glioma cohorts incompletely characterized"]},{"year":null,"claim":"The downstream signaling pathways through which BCAN cleavage fragments promote glioma invasion, the molecular basis of non-GPI membrane association of underglycosylated isoforms, and BCAN's precise structural role within perineuronal nets remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No receptor or signaling cascade identified for BCAN cleavage fragments","Structural basis of BCAN incorporation into perineuronal nets not determined","No conditional knockout in adult mammalian brain to separate developmental from maintenance roles"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,9]}],"localization":[{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[0,2,9]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,3]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,6,7]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,2,9]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[9]}],"complexes":[],"partners":["ADAMTS4","NTRK1","PCLO"],"other_free_text":[]},"mechanistic_narrative":"BCAN (brevican/BEHAB) is a brain-specific chondroitin sulfate proteoglycan of the hyaluronan-binding (PTR/lectican) family that organizes the neural extracellular matrix and whose proteolytic processing is a key determinant of glioma invasiveness. BCAN exists as secreted and GPI-anchored isoforms, and its cleavage at Glu395-Ser396 by ADAMTS4 generates N- and C-terminal fragments that each promote glioma cell invasion and tumor progression in vivo; a cleavage-resistant mutant abolishes these pro-invasive effects [PMID:10801887, PMID:18398576, PMID:11585735]. In gliomas, additional underglycosylated and oversialylated isoforms associate with the tumor cell surface through a non-GPI mechanism and are selectively expressed in high-grade tumors [PMID:12799382, PMID:16061654]. In normal brain, astrocyte-secreted brevican contributes to perineuronal net integrity, synapse stability, and nerve conduction, as demonstrated by a BCAN deletion causing paroxysmal hypertonicity (episodic falling syndrome) in dogs [PMID:21821125]."},"prefetch_data":{"uniprot":{"accession":"Q96GW7","full_name":"Brevican core protein","aliases":["Brain-enriched hyaluronan-binding protein","BEHAB","Chondroitin sulfate proteoglycan 7"],"length_aa":911,"mass_kda":99.1,"function":"May play a role in the terminally differentiating and the adult nervous system during postnatal development. Could stabilize interactions between hyaluronan (HA) and brain proteoglycans","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q96GW7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCAN","classification":"Not Classified","n_dependent_lines":69,"n_total_lines":1208,"dependency_fraction":0.057119205298013245},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCAN","total_profiled":1310},"omim":[{"mim_id":"619726","title":"HYALURONAN AND PROTEOGLYCAN LINK PROTEIN 2; HAPLN2","url":"https://www.omim.org/entry/619726"},{"mim_id":"619710","title":"HYALURONAN AND PROTEOGLYCAN LINK PROTEIN 4; HAPLN4","url":"https://www.omim.org/entry/619710"},{"mim_id":"600347","title":"BREVICAN; BCAN","url":"https://www.omim.org/entry/600347"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":236.6}],"url":"https://www.proteinatlas.org/search/BCAN"},"hgnc":{"alias_symbol":["BEHAB","MGC13038","CSPG7"],"prev_symbol":[]},"alphafold":{"accession":"Q96GW7","domains":[{"cath_id":"2.60.40.10","chopping":"36-66_73-156","consensus_level":"high","plddt":89.924,"start":36,"end":156},{"cath_id":"3.10.100.10","chopping":"158-356","consensus_level":"medium","plddt":90.6111,"start":158,"end":356},{"cath_id":"2.10.25.10","chopping":"655-687","consensus_level":"medium","plddt":86.6255,"start":655,"end":687},{"cath_id":"3.10.100.10","chopping":"689-813","consensus_level":"high","plddt":91.319,"start":689,"end":813},{"cath_id":"2.10.70.10","chopping":"825-874","consensus_level":"high","plddt":87.981,"start":825,"end":874}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96GW7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96GW7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96GW7-F1-predicted_aligned_error_v6.png","plddt_mean":68.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCAN","jax_strain_url":"https://www.jax.org/strain/search?query=BCAN"},"sequence":{"accession":"Q96GW7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96GW7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96GW7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96GW7"}},"corpus_meta":[{"pmid":"10801887","id":"PMC_10801887","title":"Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10801887","citation_count":162,"is_preprint":false},{"pmid":"7512973","id":"PMC_7512973","title":"BEHAB, a new member of the proteoglycan tandem repeat family of hyaluronan-binding proteins that is restricted to the brain.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7512973","citation_count":88,"is_preprint":false},{"pmid":"10364444","id":"PMC_10364444","title":"Intracranial injury acutely induces the expression of the secreted isoform of the CNS-specific hyaluronan-binding protein BEHAB/brevican.","date":"1999","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10364444","citation_count":77,"is_preprint":false},{"pmid":"8625302","id":"PMC_8625302","title":"BEHAB (brain enriched hyaluronan binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8625302","citation_count":76,"is_preprint":false},{"pmid":"18398576","id":"PMC_18398576","title":"BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion.","date":"2008","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18398576","citation_count":74,"is_preprint":false},{"pmid":"28695888","id":"PMC_28695888","title":"Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28695888","citation_count":57,"is_preprint":false},{"pmid":"29872694","id":"PMC_29872694","title":"Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.","date":"2017","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29872694","citation_count":53,"is_preprint":false},{"pmid":"22253609","id":"PMC_22253609","title":"Parallel mapping and simultaneous sequencing reveals deletions in BCAN and FAM83H associated with discrete inherited disorders in a domestic dog breed.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22253609","citation_count":52,"is_preprint":false},{"pmid":"16061654","id":"PMC_16061654","title":"Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16061654","citation_count":51,"is_preprint":false},{"pmid":"7869103","id":"PMC_7869103","title":"The CNS-specific hyaluronan-binding protein BEHAB is expressed in ventricular zones coincident with gliogenesis.","date":"1995","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/7869103","citation_count":47,"is_preprint":false},{"pmid":"21821125","id":"PMC_21821125","title":"A canine BCAN microdeletion associated with episodic falling syndrome.","date":"2011","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/21821125","citation_count":43,"is_preprint":false},{"pmid":"12799382","id":"PMC_12799382","title":"A novel membrane-associated glycovariant of BEHAB/brevican is up-regulated during rat brain development and in a rat model of invasive glioma.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12799382","citation_count":43,"is_preprint":false},{"pmid":"9811619","id":"PMC_9811619","title":"BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility.","date":"1998","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/9811619","citation_count":41,"is_preprint":false},{"pmid":"11496922","id":"PMC_11496922","title":"Glial tumor invasion: a role for the upregulation and cleavage of BEHAB/brevican.","date":"2001","source":"The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11496922","citation_count":36,"is_preprint":false},{"pmid":"11585735","id":"PMC_11585735","title":"Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11585735","citation_count":32,"is_preprint":false},{"pmid":"11054543","id":"PMC_11054543","title":"cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma.","date":"2000","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11054543","citation_count":28,"is_preprint":false},{"pmid":"37726400","id":"PMC_37726400","title":"LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer.","date":"2023","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/37726400","citation_count":17,"is_preprint":false},{"pmid":"32845505","id":"PMC_32845505","title":"The Role of BEHAB/Brevican in the Tumor Microenvironment: Mediating Glioma Cell Invasion and Motility.","date":"2020","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/32845505","citation_count":12,"is_preprint":false},{"pmid":"11197728","id":"PMC_11197728","title":"BEHAB/brevican: an extracellular matrix component associated with invasive glioma.","date":"2000","source":"Clinical neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/11197728","citation_count":11,"is_preprint":false},{"pmid":"11873941","id":"PMC_11873941","title":"Human BRAL1 and BCAN genes that belong to the link-module superfamily are tandemly arranged on chromosome 1q21-23.","date":"2002","source":"Acta medica Okayama","url":"https://pubmed.ncbi.nlm.nih.gov/11873941","citation_count":6,"is_preprint":false},{"pmid":"20439034","id":"PMC_20439034","title":"BCAN Think Tank session 3: Prevention of bladder cancer.","date":"2010","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20439034","citation_count":6,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.01.28.635270","title":"Decoding Phenotypic Variability in Osteogenesis Imperfecta: Zebrafish as a Model for Molecular and Ultrastructural Insights","date":"2025-01-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.28.635270","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.03.662734","title":"Piccolo Regulates Secretion of the Extracellular Matrix Components Brevican and Tenascin R from Astrocytes to Drive Synapse Formation: Implications for Pontocerebellar Hypoplasia Type 3 (PCH3)","date":"2025-07-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.03.662734","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.10.25320337","title":"Profiling of early-onset bladder cancer identifies key genomic alterations and potential targets","date":"2025-01-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.10.25320337","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.16.25320290","title":"Plasma Proteomic Signatures of Physical Activity Provide Insights into Biological Impacts of Physical Activity and its Protective Role Against Dementia","date":"2025-01-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.16.25320290","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":13185,"output_tokens":2629,"usd":0.039495},"stage2":{"model":"claude-opus-4-6","input_tokens":5973,"output_tokens":2553,"usd":0.140535},"total_usd":0.18003,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"BEHAB/brevican was identified as a brain-specific extracellular matrix protein belonging to the proteoglycan tandem repeat (PTR) family of hyaluronan-binding proteins, with CNS-restricted expression and developmental regulation consistent with a role in stabilizing hyaluronan-proteoglycan interactions in the brain ECM.\",\n      \"method\": \"cDNA cloning, sequence homology analysis, Northern blot/in situ hybridization for expression profiling\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — foundational cloning/characterization paper; single lab with sequence-based functional inference, replicated across species\",\n      \"pmids\": [\"7512973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"BEHAB/brevican expression in ventricular zones is temporally coincident with gliogenesis (not neurogenesis), suggesting a role in glial cell generation or differentiation during CNS development.\",\n      \"method\": \"In situ hybridization and immunohistochemistry during rat CNS development\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization experiment with developmental timing correlation; single lab\",\n      \"pmids\": [\"7869103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BEHAB/brevican exists as two isoforms: a secreted form and a GPI-anchored cell-surface form; following intracranial stab wound injury, only the secreted isoform is upregulated during reactive gliosis, temporally paralleling the gliotic response.\",\n      \"method\": \"Immunoblotting, RNase protection assay, GPI-anchor characterization, stab wound model in adult rat brain\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct fractionation and isoform-specific detection with functional context; single lab\",\n      \"pmids\": [\"10364444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BEHAB/brevican is cleaved at a specific Glu(395)-Ser(396) site by a constitutively secreted ADAMTS family metalloproteinase, specifically identified as ADAMTS4, in invasive glioma cells (CNS-1 line).\",\n      \"method\": \"Neoepitope antibody against cleavage site, protease inhibitor panel, RT-PCR, immunoblotting of CNS-1 conditioned medium\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (neoepitope antibody, inhibitor profiling, RT-PCR, immunoblot) in single well-cited study; foundational paper\",\n      \"pmids\": [\"10801887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Human BEHAB/brevican maps to chromosome 1q31 and is expressed as two isoforms (secreted and GPI-anchored); the secreted isoform is developmentally regulated in human cortex and both isoforms are upregulated ~7-fold in glioma.\",\n      \"method\": \"RNase protection analysis, chromosomal mapping, cDNA cloning\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct isoform characterization and quantification; single lab\",\n      \"pmids\": [\"11054543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Overexpression of full-length BEHAB/brevican, its N-terminal cleavage product, or C-terminal cleavage product in CNS-1 glioma cells significantly increased tumor aggressiveness and shortened survival in intracranial rat grafts, establishing that both upregulation and proteolytic cleavage of BEHAB/brevican drive glioma invasion.\",\n      \"method\": \"Stable transfection of glioma cell lines with BEHAB/brevican constructs, intracranial rat graft model, survival analysis, histology\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss/gain-of-function with defined phenotypic readout; single lab\",\n      \"pmids\": [\"11585735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A novel underglycosylated BEHAB/brevican isoform (B/b130), lacking glycosaminoglycan chains and most N-linked sugars, associates with the cell membrane via a calcium-independent mechanism distinct from GPI-anchoring, and is the major isoform upregulated in invasive glioma.\",\n      \"method\": \"Subcellular fractionation, glycosidase treatment, immunoblotting, rat glioma model\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical fractionation and glycan characterization with functional context; single lab\",\n      \"pmids\": [\"12799382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Two novel glioma-specific BEHAB/brevican isoforms exist: B/b(sia), an oversialylated form, and B/b(Deltag), which lacks most carbohydrates and associates with the cell surface by a mechanism distinct from GPI-anchoring; B/b(Deltag) is expressed in all high-grade gliomas but absent from indolent oligodendrogliomas.\",\n      \"method\": \"Biochemical glycan characterization, immunoblotting, surface biotinylation, GPI-anchor disruption assay, analysis of human glioma samples\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods; single lab\",\n      \"pmids\": [\"16061654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ADAMTS-mediated proteolytic cleavage of BEHAB/brevican at the Glu(395)-Ser(396) site is necessary for its pro-invasive function; a site-specific cleavage-resistant mutant (396SRG→NVY) fails to enhance glioma cell invasion in vitro or tumor progression in vivo, and does not exert dominant-negative effects on endogenous protein.\",\n      \"method\": \"Site-directed mutagenesis, in vitro invasion assay, intracranial glioma mouse model, immunoblotting\",\n      \"journal\": \"Journal of neuro-oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — active-site mutagenesis combined with in vitro and in vivo functional assays; mechanistically definitive\",\n      \"pmids\": [\"18398576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A 15.7 kb deletion spanning three exons of BCAN (encoding brevican) is causally associated with episodic falling syndrome in Cavalier King Charles Spaniels, a paroxysmal hypertonicity disorder, implicating brevican's role in perineuronal net formation, synapse stability, and nerve conduction.\",\n      \"method\": \"Genome-wide association study, targeted resequencing, deletion breakpoint mapping, MLPA genotyping\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic mapping with deletion identification in canine ortholog model; functional inference from known biology\",\n      \"pmids\": [\"21821125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A chromosomal microdeletion generating a BCAN-NTRK1 gene fusion acts as a potent oncogenic driver of high-grade gliomas, and tumors harboring this fusion are sensitive to the TRK inhibitor entrectinib.\",\n      \"method\": \"CRISPR-based somatic chromosomal engineering ex vivo and in vivo, mouse glioma models, pharmacological inhibition\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome editing to generate fusion, multiple mouse models, pharmacological rescue; strong mechanistic demonstration\",\n      \"pmids\": [\"28695888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Piccolo regulates secretion of brevican (BCAN) and tenascin-R from astrocytes; loss of Piccolo (Pclo gt/gt) causes impaired extracellular brevican levels, fragmented Golgi in astrocytes, reduced synapse density in co-cultured neurons, and altered network activity—rescued by wild-type astrocyte-conditioned media.\",\n      \"method\": \"Pclo gt/gt rat model, immunohistochemistry, astrocyte-conditioned media rescue, co-culture synapse density assay, mEPSC recording, RNA-seq\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in a genetic model with functional rescue; preprint, not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"BEHAB/brevican (BCAN) is a brain-specific chondroitin sulfate proteoglycan/hyaluronan-binding protein that exists as secreted and GPI-anchored isoforms and is proteolytically cleaved at Glu395-Ser396 by ADAMTS4; this ADAMTS-mediated cleavage is necessary for BCAN's pro-invasive function in gliomas, while in normal brain BCAN is secreted from astrocytes (regulated by Piccolo at the Golgi) to support perineuronal net formation, synapse stability, and nerve conduction velocity.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BCAN (brevican/BEHAB) is a brain-specific chondroitin sulfate proteoglycan of the hyaluronan-binding (PTR/lectican) family that organizes the neural extracellular matrix and whose proteolytic processing is a key determinant of glioma invasiveness. BCAN exists as secreted and GPI-anchored isoforms, and its cleavage at Glu395-Ser396 by ADAMTS4 generates N- and C-terminal fragments that each promote glioma cell invasion and tumor progression in vivo; a cleavage-resistant mutant abolishes these pro-invasive effects [PMID:10801887, PMID:18398576, PMID:11585735]. In gliomas, additional underglycosylated and oversialylated isoforms associate with the tumor cell surface through a non-GPI mechanism and are selectively expressed in high-grade tumors [PMID:12799382, PMID:16061654]. In normal brain, astrocyte-secreted brevican contributes to perineuronal net integrity, synapse stability, and nerve conduction, as demonstrated by a BCAN deletion causing paroxysmal hypertonicity (episodic falling syndrome) in dogs [PMID:21821125].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of BCAN as a novel brain-restricted hyaluronan-binding proteoglycan established the gene's ECM identity and CNS specificity, opening the question of its functional role in neural tissue.\",\n      \"evidence\": \"cDNA cloning, sequence homology, and Northern blot/in situ expression profiling in rat brain\",\n      \"pmids\": [\"7512973\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No functional assays performed; role inferred from domain architecture only\",\n        \"Expression profiling limited to rodent\"\n      ]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Temporal coincidence of BCAN expression with gliogenesis rather than neurogenesis suggested a developmental role in glial lineage specification, raising the question of whether BCAN is functionally required for gliogenesis.\",\n      \"evidence\": \"In situ hybridization and immunohistochemistry during rat CNS development\",\n      \"pmids\": [\"7869103\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Correlative timing only; no loss-of-function test of gliogenesis requirement\",\n        \"No mechanism linking BCAN to progenitor cell fate\"\n      ]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery of secreted and GPI-anchored BCAN isoforms, with selective upregulation of the secreted form after brain injury, established isoform-specific regulation and implicated BCAN in the gliotic response.\",\n      \"evidence\": \"Immunoblotting, RNase protection assay, GPI-anchor characterization, adult rat stab-wound model\",\n      \"pmids\": [\"10364444\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No loss-of-function to test whether secreted isoform upregulation is required for gliosis\",\n        \"Mechanism of isoform-specific transcriptional regulation unknown\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of ADAMTS4 as the protease cleaving BCAN at Glu395-Ser396 in glioma cells defined the specific proteolytic event central to BCAN processing, setting up the question of whether cleavage is functionally required for invasion.\",\n      \"evidence\": \"Neoepitope antibody, protease inhibitor profiling, RT-PCR, and immunoblotting of CNS-1 glioma conditioned medium\",\n      \"pmids\": [\"10801887\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Cleavage shown in one glioma cell line only\",\n        \"Functional consequence of cleavage not yet tested\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Overexpression of full-length BCAN or either cleavage fragment enhanced glioma aggressiveness in vivo, establishing that both upregulation and proteolytic processing of BCAN promote tumor invasion.\",\n      \"evidence\": \"Stable transfection of glioma cells, intracranial rat graft model, survival analysis\",\n      \"pmids\": [\"11585735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Gain-of-function only; no knockdown to test necessity\",\n        \"Mechanism by which cleavage fragments promote invasion unknown\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery of an underglycosylated, membrane-associated BCAN isoform (B/b130) as the predominant form in glioma revealed that post-translational glycan modification diversifies BCAN cell-surface biology beyond the canonical secreted/GPI dichotomy.\",\n      \"evidence\": \"Subcellular fractionation, glycosidase treatment, immunoblotting in rat glioma model\",\n      \"pmids\": [\"12799382\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Membrane-association mechanism for the non-GPI form unresolved\",\n        \"Functional contribution of underglycosylated isoform to invasion not directly tested\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of glioma-specific oversialylated and hypoglycosylated BCAN isoforms that correlate with tumor grade showed that aberrant glycosylation marks aggressive tumors and could serve as biomarkers.\",\n      \"evidence\": \"Glycan characterization, surface biotinylation, GPI-anchor disruption, human glioma tissue analysis\",\n      \"pmids\": [\"16061654\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Causal role of altered glycosylation in invasion not demonstrated\",\n        \"Mechanism of non-GPI cell-surface retention still unknown\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"A cleavage-resistant BCAN mutant failed to enhance invasion in vitro or tumor progression in vivo, definitively establishing that ADAMTS-mediated cleavage at Glu395-Ser396 is necessary — not merely permissive — for BCAN's pro-invasive activity.\",\n      \"evidence\": \"Site-directed mutagenesis (396SRG→NVY), in vitro invasion assay, intracranial mouse glioma model\",\n      \"pmids\": [\"18398576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Downstream signaling pathways engaged by cleavage fragments remain unidentified\",\n        \"Whether other ADAMTS family members contribute to cleavage in vivo is untested\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"A 15.7 kb BCAN deletion causing episodic falling syndrome in dogs provided the first genetic evidence that BCAN is required for normal neuronal function, linking it to perineuronal net integrity and synaptic/conduction stability.\",\n      \"evidence\": \"GWAS, targeted resequencing, deletion breakpoint mapping in Cavalier King Charles Spaniels\",\n      \"pmids\": [\"21821125\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Canine model; no human Mendelian disorder confirmed\",\n        \"No rescue experiment to prove causality of the deletion alone\",\n        \"Specific perineuronal net structural defect not visualized\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CRISPR-engineered BCAN-NTRK1 fusion proved to be an oncogenic driver of high-grade glioma and conferred sensitivity to TRK inhibition, demonstrating that the BCAN locus participates in oncogenic rearrangements beyond its ECM functions.\",\n      \"evidence\": \"CRISPR somatic engineering of chromosomal deletion in mouse neural progenitors, in vivo tumorigenesis, entrectinib treatment\",\n      \"pmids\": [\"28695888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Oncogenic activity driven by NTRK1 kinase domain, not BCAN protein function per se\",\n        \"Frequency and clinical significance of BCAN-NTRK1 fusions in human glioma cohorts incompletely characterized\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The downstream signaling pathways through which BCAN cleavage fragments promote glioma invasion, the molecular basis of non-GPI membrane association of underglycosylated isoforms, and BCAN's precise structural role within perineuronal nets remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No receptor or signaling cascade identified for BCAN cleavage fragments\",\n        \"Structural basis of BCAN incorporation into perineuronal nets not determined\",\n        \"No conditional knockout in adult mammalian brain to separate developmental from maintenance roles\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [0, 2, 9]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 3]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 6, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 2, 9]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ADAMTS4\",\n      \"NTRK1\",\n      \"PCLO\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}